Original Title: Seguridad, efectividad y eficiencia del Catéter de Resucitación Endovascular para Oclusión de la Aorta (REBOA)

Authors' objectives: To determine the safety, effectiveness and efficiency of the REBOA technique in patients with abdominal, retroperitoneal and pelvic haemorrhage or with Placental accreta spectrum disorder (PAD).

Authors' results and conclusions: CONCLUSIONS: Therapeutic REBOA • Therapeutic REBOA is effective in reducing 24-hour mortality when compared to resuscitative thoracotomy (OR= 0.26; 95%CI: 0.20 – 0.34). The certainty of the evidence was assessed as low. • Overall, REBOA reduces in-hospital mortality compared to any comparator (OR= 0.90; 95%CI: 0.81 – 0.99) (very low certainty of evidence). Especially in the comparison with TR (OR= 0.30; 95%CI: 0.26 – 0.35), the certainty of evidence was assessed as moderate. • REBOA also improves systolic blood pressure after occlusion more than any comparator (MD= 41.03 mmHg; 95% CI: 36.77 – 45.29). The certainty of the evidence was assessed as low. • REBOA is less safe than its comparators in terms of lower limb amputation, acute kidney damage, paraplegia with a certainty of evidence rated as low. and acute lung damage, with a certainty of evidence rated as very low. • REBOA wouldn’t be efficient according to the only identified study in the UK context comparing with TR. Preventive REBOA • REBOA reduces the number of hysterectomies when used as a preventive measure in deliveries of women with PAD (OR= 0.21; 95%CI: 0.08 – 0.53). Certainty of evidence rated as low. • Preventive REBOA also reduces the number of women admitted to the ICU (OR= 0.18; 95%CI: 0.08 – 0.42) (certainty of evidence very low). Similarly, preventive REBOA reduces transfusion requirements and the duration of surgery for women with PAD (certainty of evidence very low). • Preventive REBOA has no more adverse effects or complications than its comparators (certainty of evidence very low).

Authors' methods: A systematic review of the available scientific literature on the effectiveness, safety and cost-effectiveness of REBOA in patients with traumatic abdomino-pelvic haemorrhage (therapeutic REBOA) or with PAD (preventive REBOA) was carried out.

Project Status: Completed

Year Published: 2024

URL for published report: https://repisalud.isciii.es/rest/api/core/bitstreams/a87b1dea-593c-421e-9cf1-d2e68bac91d3/content

URL for additional information: https://redets.sanidad.gob.es/productos/buscarProductos.do?metodo=detalle&id=1229

English language abstract: An English language summary is available

Publication Type: Full HTA

Country: Spain

Organisation Name: Agencia de Evaluacion de Tecnologias Sanitarias

Contact Address: Instituto de Salud "Carlos III", Calle Sinesio Delgado 6, Pabellon 4, 28029 Madrid, Spain. Tel: +34 9 1 822 2005; Fax: +34 9 1 387 7841;

Contact Name: Esther E. García Carpintero

Contact Email: eegarcia@isciii.es

Copyright: Agencia de Evaluacion de Tecnologias Sanitarias